Cancer Stem Cells Market Set to Reach $6.8 Billion by 2035

Cancer stem cells market was valued at $2.8 billion in 2025 and is projected to reach $6.8 billion by 2035, growing at a CAGR of 9.3% during the forecast period (2026-2035).The global Cancer Stem Cells (CSCs) market is experiencing accelerated growth as cancer research increasingly focuses on targeting CSCs to prevent tumor recurrence and therapy resistance. CSC?related cell therapies are emerging as a vital segment in oncology, attracting substantial attention from pharmaceutical and biotechnology companies. Increasing global investment in CSC-focused therapeutics is driving the expansion of specialized research centers and state-of-the-art manufacturing infrastructure. These developments are facilitating the clinical translation of innovative therapies, including immunotherapies, targeted small molecules, and combination treatments.

Browse the full report description of “Cancer Stem Cells Market Size, Share & Trends Analysis Report by Therapy (Targeted Cancer Stem Cells Therapy and Stem Cell-Based Cancer Therapy), by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer and Other) and by Application (Drug Discovery, Diagnostics, Regenerative Medicine, Translational / Preclinical Research and Others), Forecast (2026-2035)” at https://www.omrglobal.com/industry-reports/cancer-stem-cells-market

For instance, in March 2026, AstraZeneca announced plans to build a cell therapy manufacturing and innovation center in Shanghai, aiming to become the first global drugmaker with end-to-end CAR?T therapy capabilities in China. The facility will produce and supply CAR?T therapies for China and other Asian markets, alongside a planned radio conjugate drug production base in Guangzhou for oncology treatments across the Asia-Pacific region. This investment is part of AstraZeneca’s broader $15 billion China strategy through 2030, complementing prior hubs in Shanghai (2024) and Beijing (2025). Furthermore, private and public stakeholders are collaborating to fund advanced R&D programs, fostering an ecosystem that supports rapid innovation and commercialization. As a result, the market is poised for sustained growth, with enhanced infrastructure enabling more effective CSC-targeted treatments. The expanding investment landscape underscores the strategic importance of CSC therapeutics, positioning this segment as a key driver in improving cancer patient outcomes globally.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Therapy
• Cancer Type
• Application

• Competitive Landscape – AbbVie Inc., AstraZeneca PLC, Novartis AG, Pfizer Inc., and Merck & Co. Inc., among others, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cancer Stem Cells (CSCs) Market Report Segment

By Therapy

• Targeted Cancer Stem Cells Therapy
• Stem Cell-Based Cancer Therapy

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Other Cancers

By Application

• Drug Discovery
• Diagnostics
• Regenerative Medicine
• Translational / Preclinical Research
• Others

Global Cancer Stem Cells (CSCs) Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cancer-stem-cells-market